Brian A Dougherty
Overview
Explore the profile of Brian A Dougherty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollis R, Churchman M, Grimes G, Meynert A, Gautier P, McMahon L, et al.
Eur J Cancer
. 2025 Feb;
219:115299.
PMID: 39955805
Background: Half of high grade serous tubo-ovarian carcinomas (HGSOC) demonstrate homologous recombination repair (HRR) deficiency, most commonly through germline or somatic pathogenic variants in BRCA1/2 (gBRCA1/2 or sBRCA1/2). gBRCA1/2 is...
2.
Stetson D, Ahmed A, Xu X, Nuttall B, Lubinski T, Johnson J, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-9.
PMID: 35100678
Purpose: Discordance between plasma and tumor variant calling has been attributed primarily to tumor heterogeneity, whereas technical variables remain largely unexplored. Materials And Methods: To measure these variables, we tested...
3.
Hodgson D, Brown J, Dearden S, Lai Z, Elks C, Milenkova T, et al.
Gynecol Oncol
. 2021 Nov;
163(3):563-568.
PMID: 34742578
Objective: Maintenance olaparib provided a progression-free survival benefit in the phase III SOLO2 trial (NCT01874353) in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (BRCAm). However, questions remain...
4.
Collins G, Clevenger T, Burke K, Yang B, MacDonald A, Cunningham D, et al.
Leuk Lymphoma
. 2021 Jul;
62(11):2625-2636.
PMID: 34269152
In a phase 1b study of acalabrutinib (a covalent Bruton tyrosine kinase (BTK) inhibitor) in combination with vistusertib (a dual mTORC1/2 inhibitor) in patients with relapsed/refractory diffuse large B-cell lymphoma...
5.
Hodgson D, Dougherty B, Lai Z, Fielding A, Grinsted L, Spencer S, et al.
Br J Cancer
. 2018 Oct;
119(11):1401-1409.
PMID: 30353044
Background: Olaparib (Lynparza™) is a PARP inhibitor approved for advanced BRCA-mutated (BRCAm) ovarian cancer. PARP inhibitors may benefit patients whose tumours are dysfunctional in DNA repair mechanisms unrelated to BRCA1/2....
6.
Borodovsky A, McQuiston T, Stetson D, Ahmed A, Whitston D, Zhang J, et al.
Mol Cancer
. 2017 Dec;
16(1):177.
PMID: 29212548
Efforts to develop effective cancer therapeutics have been hindered by a lack of clinically predictive preclinical models which recapitulate this complex disease. Patient derived xenograft (PDX) models have emerged as...
7.
Dougherty B, Lai Z, Hodgson D, Orr M, Hawryluk M, Sun J, et al.
Oncotarget
. 2017 May;
8(27):43653-43661.
PMID: 28525389
To gain a better understanding of the role of somatic mutations in olaparib response, next-generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned retrospective analysis...
8.
Lheureux S, Lai Z, Dougherty B, Runswick S, Hodgson D, Timms K, et al.
Clin Cancer Res
. 2017 Feb;
23(15):4086-4094.
PMID: 28223274
Maintenance therapy with olaparib has improved progression-free survival in women with high-grade serous ovarian cancer (HGSOC), particularly those harboring mutations. The objective of this study was to characterize long-term (LT)...
9.
Gootz T, Lescoe M, Dib-Hajj F, Dougherty B, He W, Della-Latta P, et al.
Antimicrob Agents Chemother
. 2009 Mar;
53(5):1998-2004.
PMID: 19258268
Carbapenem-resistant Klebsiella strains carrying Klebsiella pneumoniae carbapenemases (KPC) are endemic to New York City and are spreading across the United States and internationally. Recent studies have indicated that the KPC...
10.
Liu M, Healy M, Dougherty B, Esposito K, Maurice T, Mazzucco C, et al.
Eukaryot Cell
. 2006 Apr;
5(4):638-49.
PMID: 16607011
The discovery of novel classes of antifungal drugs depends to a certain extent on the identification of new, unexplored targets that are essential for growth of fungal pathogens. Likewise, the...